Y
Yvonne Y. Lau
Researcher at Novartis
Publications - 18
Citations - 1698
Yvonne Y. Lau is an academic researcher from Novartis. The author has contributed to research in topics: Ceritinib & Anaplastic lymphoma kinase. The author has an hindex of 9, co-authored 16 publications receiving 1497 citations.
Papers
More filters
Journal ArticleDOI
Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
Alice T. Shaw,Dong Wan Kim,Ranee Mehra,Daniel Shao-Weng Tan,Enriqueta Felip,Laura Q.M. Chow,D. Ross Camidge,Johan Vansteenkiste,Sunil Sharma,Tommaso De Pas,Gregory J. Riely,Benjamin Solomon,Juergen Wolf,Michael Thomas,Martin Schuler,Martin Schuler,Geoffrey Liu,Armando Santoro,Yvonne Y. Lau,Meredith Goldwasser,Anthony Boral,Jeffrey A. Engelman +21 more
TL;DR: Ceritinib was highly active in patients with advanced, ALK-rearranged NSCLC, including those who had had disease progression during crizotinib treatment, regardless of the presence of resistance mutations in ALK.
Journal ArticleDOI
ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 Mg or 600 Mg, Taken With a Low-Fat Meal Versus 750 Mg in Fasted State in Patients With Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC)
Byoung Chul Cho,Dong Wan Kim,Alessandra Bearz,Scott A. Laurie,Mark J. McKeage,Gloria Borra,Keunchil Park,Sang We Kim,Marwan Ghosn,Andrea Ardizzoni,Evaristo Maiello,Alastair Greystoke,Richard Yu,Karen Osborne,Wen Gu,Jeffrey W. Scott,Vanessa Q. Passos,Yvonne Y. Lau,Anna Wrona +18 more
TL;DR: Ceritinib, 450 mg with food, had similar exposure and a more favorable GI safety profile than cerit inib, 750 mg in fasted patients with ALK‐positive NSCLC.
Journal ArticleDOI
Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)–Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study
Byoung Chul Cho,Radka Obermannova,Alessandra Bearz,Mark J. McKeage,Dong Wang Kim,Ullas Batra,Gloria Borra,Sergey Orlov,Sang We Kim,Sarayut Lucien Geater,Pieter E. Postmus,Scott A. Laurie,Keunchil Park,Cheng-Ta Yang,Andrea Ardizzoni,Anna Cecilia Bettini,Gilberto de Castro,Flavia Kiertsman,Zhe Chen,Yvonne Y. Lau,Kalyanee Viraswami-Appanna,Vanessa Q. Passos,Rafal Dziadziuszko +22 more
TL;DR: Ceritinib at a dose of 450 mg with food compared to 750-mg fasted showed consistent efficacy and less gastrointestinal toxicity.
Journal ArticleDOI
Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non–Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study
Enriqueta Felip,Filippo de Braud,Michela Maur,Herbert H. Loong,Alice T. Shaw,Johan Vansteenkiste,Thomas John,Geoffrey Liu,Martijn P. Lolkema,Giovanni Selvaggi,Vanessa Giannone,Pilar Cazorla,Jason Baum,O. Alejandro Balbin,Luojun Victor Wang,Yvonne Y. Lau,Jeffrey W. Scott,Daniel Shao-Weng Tan +17 more
TL;DR: Ceritinib plus nivolumab has activity; ORR appears to correlate with PD-L1 at baseline, especially rash, which is more common than with either single agent.
Journal ArticleDOI
Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects.
TL;DR: It is essential to avoid any type of meal during dosing of ceritinib because the intake of food may increase the occurrence of exposure‐dependent, non‐GI toxicities at the labeled dose of 750 mg daily during fasting.